64 results on '"Renshaw, Andrew A."'
Search Results
2. Patients undergoing reverse total shoulder arthroplasty have less pain and require fewer opioid pain medications compared to anatomic total shoulder arthroplasty in the early postoperative period: a retrospective review
3. High-grade urothelial carcinoma with hypochromatic chromatin in urine cytology
4. Risk stratification of HIV infection for patients needing molecular confirmation with the Abbott 4th generation Architect System
5. Herpes simplex virus infections in pulmonary cytology rarely represent pulmonary disease but remain a marker for mortality risk
6. Solar Neutrino Results from Super-Kamiokande
7. Issues in reporting cytology: From headers and critical values to categorical data and natural language parsers
8. Respiratory syncytial virus infection is strongly correlated with decreased mean platelet volume
9. Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality
10. Research and Development for a Gadolinium Doped Water Cherenkov Detector
11. 6 - Neoplasia folicular, tipo células de Hürthle (oncocítica)/sospechosa de neoplasia folicular, tipo células de Hürthle (oncocítica)
12. 4 - Atipia de significado indeterminado/lesión folicular de significado indeterminado
13. Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group
14. Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations
15. 15 - Kidney and Adrenal Gland
16. 3 - Urine and Bladder Washings
17. Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death
18. Gleason Pattern 5 Prostate Cancer: Further Stratification of Patients With High-Risk Disease and Implications for Future Randomized Trials
19. Effect of Definition of Preradiotherapy Prostate-Specific Antigen Velocity on Its Association with Prostate Cancer-Specific Mortality and All-Cause Mortality
20. Prediagnostic Prostate-Specific Antigen Velocity and Probability of Detecting High-Grade Prostate Cancer
21. Identifying Men Diagnosed With Clinically Localized Prostate Cancer Who are at High Risk for Death From Prostate Cancer
22. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level
23. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era
24. Pretreatment predictors of posttreatment PSA doubling times for patients undergoing three-dimensional conformal radiotherapy for clinically localized prostate cancer
25. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer
26. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer
27. The impact of pathology review on treatment recommendations for patients with adenocarcinoma of the prostate
28. Sclerosis of the clavicle––A challenging diagnosis
29. Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core?
30. Rescreening in cervical cytology for quality control: When bad data is worse than no data or what works, what doesn't, and why
31. Pretreatment Predictors of Time to Cancer Specific Death After Prostate Specific Antigen Failure
32. Colaboradores
33. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era
34. Gene expression correlates of clinical prostate cancer behavior
35. Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce
36. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer
37. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era
38. Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer
39. Lower Prostate Specific Antigen Outcome Than Expected Following Radical Prostatectomy in Patients With High Grade Prostate and a Prostatic Specific Antigen Level of 4 Ng/Ml. or Less
40. Transition from In Situ to Invasive Testicular Germ Cell Neoplasia is Associated with the Loss of p21 and Gain of mdm-2 Expression
41. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
42. Optimizing patient selection for prostate monotherapy
43. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening
44. PERINEURAL INVASION AS A PREDICTOR OF BIOCHEMICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY FOR SELECT MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER
45. Evaluation of Cyclin Expression in Testicular Germ Cell Tumors: Cyclin E Correlates with Tumor Type, Advanced Clinical Stage, and Pulmonary Metastasis
46. Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma
47. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage
48. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA ≤ 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy
49. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy
50. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.